Circadian and sleep disorders in Parkinson's disease

Experimental Neurology

Volumn 243, Issue , 2013, Pages 45-56

  Videnovic, Aleksandar ^a   Golombek, Diego ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

Circadian; Dopamine; Parkinson's; RBD; RLS; Sleep; Sleep apnea; Sleepiness; Somnolence

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMANTADINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CLONAZEPAM; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE ACTIVE TRANSPORTER; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; GABAPENTIN ENACARBIL; LEVODOPA; MELATONIN; MODAFINIL; OREXIN; PRAMIPEXOLE; RAMELTEON; ROPINIROLE; SELEGILINE; TRANSCRIPTION FACTOR CLOCK; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ALERTNESS; BEDTIME DOSAGE; BRAIN DEPTH STIMULATION; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL FEATURE; CLOCK GENE; DAYTIME SOMNOLENCE; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; EVENING DOSAGE; EXCESSIVE DAYTIME SOMNOLENCE; HUMAN; INSOMNIA; LIGHT EXPOSURE; LOW DRUG DOSE; NIGHT SLEEP; NOCTURIA; NONHUMAN; NONREM SLEEP; PARASOMNIA; PARKINSON DISEASE; PERIODIC LIMB MOVEMENT DISORDER; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; REM SLEEP; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; SLEEP; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SLEEP WAKING CYCLE; SUPRACHIASMATIC NUCLEUS;

ANIMALS; CIRCADIAN RHYTHM; DOPAMINE; HUMANS; PARKINSON DISEASE; SLEEP DISORDERS; SLEEP STAGES;

EID: 84875378777     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.08.018     Document Type: Review

References (241)

1. Aarsland D., Alves G., Larsen J.P. Disorders of motivation, sexual conduct, and sleep in Parkinson's disease. Adv. Neurol. 2005, 96:56-64.
2. AASM The International Classification of Sleep Disorders 2005, American Academy of Sleep Medicine, Westchester, IL. 2nd ed.
3. Abbott R.D., Ross G.W., White L.R., Tanner C.M., Masaki K.H., Nelson J.S., Curb J.D., Petrovitch H. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005, 65:1442-1446.
4. Adler C.H., Thorpy M.J. Sleep issues in Parkinson's disease. Neurology 2005, 64:S12-S20.
5. Adler C.H., Caviness J.N., Hentz J.G., Lind M., Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov. Disord. 2003, 18:287-293.
6. Allen R.P., Barker P.B., Wehrl F., Song H.K., Earley C.J. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001, 56:263-265.
7. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003, 4:101-119.
8. Almirall H., Pigarev I., de la Calzada M.D., Pigareva M., Herrero M.T., Sagales T. Nocturnal sleep structure and temperature slope in MPTP treated monkeys. J. Neural Transm. 1999, 106:1125-1134.
9. Almirall H., Bautista V., Sanchez-Bahillo A., Trinidad-Herrero M. Ultradian and circadian body temperature and activity rhythms in chronic MPTP treated monkeys. Neurophysiol. Clin. 2001, 31:161-170.
10. Antonini A., Landi A., Mariani C., DeNotaris R., Pezzoli G. Deep brain stimulation and its effect on sleep in Parkinson's disease. Sleep Med. 2004, 5:211-214.
11. Archibald N.K., Clarke M.P., Mosimann U.P., Burn D.J. The retina in Parkinson's disease. Brain 2009, 132:1128-1145.
12. Arias-Vera J.R., Mansoor G.A., White W.B. Abnormalities in blood pressure regulation in a patient with Parkinson's disease. Am. J. Hypertens. 2003, 16:612-613.
13. Arnulf I., Konofal E., Merino-Andreu M., Houeto J.L., Mesnage V., Welter M.L., Lacomblez L., Golmard J.L., Derenne J.P., Agid Y. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002, 58:1019-1024.
14. Aurora R.N., Zak R.S., Maganti R.K., Auerbach S.H., Casey K.R., Chowdhuri S., Karippot A., Ramar K., Kristo D.A., Morgenthaler T.I. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J. Clin. Sleep Med. 2010, 6:85-95.
15. Barcia C., Bautista V., Sanchez-Bahillo A., Fernandez-Villalba E., Navarro-Ruis J.M., Barreiro A.F., Poza Y.P.M., Herrero M.T. Circadian determinations of cortisol, prolactin and melatonin in chronic methyl-phenyl-tetrahydropyridine-treated monkeys. Neuroendocrinology 2003, 78:118-128.
16. Barcia C., De Pablos V., Bautista-Hernandez V., Sanchez-Bahillo A., Fernandez-Barreiro A., Poza M., Herrero M.T. Measurement of motor disability in MPTP-treated macaques using a telemetry system for estimating circadian motor activity. J. Neurosci. Methods 2004, 134:59-64.
17. Barraud Q., Lambrecq V., Forni C., McGuire S., Hill M., Bioulac B., Balzamo E., Bezard E., Tison F., Ghorayeb I. Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp. Neurol. 2009, 219:574-582.
18. Ben V., Blin O., Bruguerolle B. Time-dependent striatal dopamine depletion after injection of 6-hydroxydopamine in the rat. Comparison of single bilateral and double bilateral lesions. J. Pharm. Pharmacol. 1999, 51:1405-1408.
19. Boeve B.F., Silber M.H., Saper C.B., Ferman T.J., Dickson D.W., Parisi J.E., Benarroch E.E., Ahlskog J.E., Smith G.E., Caselli R.C., Tippman-Peikert M., Olson E.J., Lin S.C., Young T., Wszolek Z., Schenck C.H., Mahowald M.W., Castillo P.R., Del Tredici K., Braak H. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007, 130:2770-2788.
20. Bonuccelli U., Del Dotto P., Lucetti C., Petrozzi L., Bernardini S., Gambaccini G., Rossi G., Piccini P. Diurnal motor variations to repeated doses of levodopa in Parkinson's disease. Clin. Neuropharmacol. 2000, 23:28-33.
21. Bordet R., Devos D., Brique S., Touitou Y., Guieu J.D., Libersa C., Destee A. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin. Neuropharmacol. 2003, 26:65-72.
22. Boulamery A., Simon N., Vidal J., Bruguerolle B. Effects of l-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study. Chronobiol. Int. 2010, 27:251-264.
23. Boutrel B., Koob G.F. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 2004, 27:1181-1194.
24. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
25. Braga-Neto P., da Silva-Junior F.P., Sueli Monte F., de Bruin P.F., de Bruin V.M. Snoring and excessive daytime sleepiness in Parkinson's disease. J. Neurol. Sci. 2004, 217:41-45.
26. Brodsky M.A., Godbold J., Roth T., Olanow C.W. Sleepiness in Parkinson's disease: a controlled study. Mov. Disord. 2003, 18:668-672.
27. Bruinink A., Lichtensteiger W., Schlumpf M. Ontogeny of diurnal rhythms of central dopamine, serotonin and spirodecanone binding sites and of motor activity in the rat. Life Sci. 1983, 33:31-38.
28. Burgess C.R., Tse G., Gillis L., Peever J.H. Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep 2010, 33:1295-1304.
29. Buysse D.J., Monk T.H., Carrier J., Begley A. Circadian patterns of sleep, sleepiness, and performance in older and younger adults. Sleep 2005, 28:1365-1376.
30. Cagnacci A., Bonuccelli U., Melis G.B., Soldani R., Piccini P., Napolitano A., Muratorio A., Fioretti P. Effect of naloxone on body temperature in postmenopausal women with Parkinson's disease. Life Sci. 1990, 46:1241-1247.
31. Cardoso S.M., Moreira P.I., Agostinho P., Pereira C., Oliveira C.R. Neurodegenerative pathways in Parkinson's disease: therapeutic strategies. Curr. Drug Targets CNS Neurol. Disord. 2005, 4:405-419.
32. Castaneda T.R., de Prado B.M., Prieto D., Mora F. Circadian rhythms of dopamine, glutamate and GABA in the striatum and nucleus accumbens of the awake rat: modulation by light. J. Pineal Res. 2004, 36:177-185.
33. Chaudhuri K.R., Pal S., DiMarco A., Whately-Smith C., Bridgman K., Mathew R., Pezzela F.R., Forbes A., Hogl B., Trenkwalder C. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2002, 73:629-635.
34. Chokroverty S.S., Rye D.B. Narcolepsy in the older adult: epidemiology, diagnosis and management. Drugs Aging 2003, 20:361-376.
35. Cicolin A., Lopiano L., Zibetti M., Torre E., Tavella A., Guastamacchia G., Terreni A., Makrydakis G., Fattori E., Lanotte M.M., Bergamasco B., Mutani R. Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients. Sleep Med. 2004, 5:207-210.
36. Claassen D.O., Josephs K.A., Ahlskog J.E., Silber M.H., Tippmann-Peikert M., Boeve B.F. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010, 75:494-499.
37. Cochen De Cock V., Abouda M., Leu S., Oudiette D., Roze E., Vidailhet M., Similowski T., Arnulf I. Is obstructive sleep apnea a problem in Parkinson's disease?. Sleep Med. 2010, 11:247-252.
38. Comella C. Sleep episodes in Parkinson's disease: more questions remain. Sleep Med. 2003, 4:267-268.
39. Comella C.L. Sleep disorders in Parkinson's disease: an overview. Mov. Disord. 2007, 22:S367-S373.
40. Comella C.L., Nardine T.M., Diederich N.J., Stebbins G.T. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology 1998, 51:526-529.
41. Czeisler C.A., Dumont M., Duffy J.F., Steinberg J.D., Richardson G.S., Brown E.N., Sanchez R., Rios C.D., Ronda J.M. Association of sleep-wake habits in older people with changes in output of circadian pacemaker. Lancet 1992, 340:933-936.
42. Daley J., Turner R., Bliwise D.L., Rye D.B. Nocturnal sleep and daytime alertness in the MPTP-treated primate. Sleep 1999, 22:S218-219. (Suppl.).
43. Dearry A., Burnside B. Dopaminergic regulation of cone retinomotor movement in isolated teleost retinas: I. Induction of cone contraction is mediated by D2 receptors. J. Neurochem. 1986, 46:1006-1021.
44. Decker M.J., Keating G., Hue G.E., Freeman A., Rye D.D. Mesolimbic dopamine's modulation of REM sleep. J. Sleep Res. 2002, 51:51-52. (supl.).
45. Devos D., Kroumova M., Bordet R., Vodougnon H., Guieu J.D., Libersa C., Destee A. Heart rate variability and Parkinson's disease severity. J. Neural. Transm. 2003, 110:997-1011.
46. Dibner C., Schibler U., Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu. Rev. Physiol. 2010, 72:517-549.
47. Diederich N.J., Vaillant M., Leischen M., Mancuso G., Golinval S., Nati R., Schlesser M. Sleep apnea syndrome in Parkinson's disease. A case-control study in 49 patients. Mov. Disord. 2005, 20:1413-1418.
48. Doi M., Yujnovsky I., Hirayama J., Malerba M., Tirotta E., Sassone-Corsi P., Borrelli E. Impaired light masking in dopamine D2 receptor-null mice. Nat. Neurosci. 2006, 9:732-734.
49. Dorenbos R., Contini M., Hirasawa H., Gustincich S., Raviola E. Expression of circadian clock genes in retinal dopaminergic cells. Vis. Neurosci. 2007, 24:573-580.
50. Dowling G.A., Mastick J., Colling E., Carter J.H., Singer C.M., Aminoff M.J. Melatonin for sleep disturbances in Parkinson's disease. Sleep Med. 2005, 6:459-466.
51. Drouot X., Moutereau S., Nguyen J.P., Lefaucheur J.P., Creange A., Remy P., Goldenberg F., d'Ortho M.P. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 2003, 61:540-543.
52. Duffield G.E., Hastings M.H., Ebling F.J. Investigation into the regulation of the circadian system by dopamine and melatonin in the adult Siberian hamster (Phodopus sungorus). J. Neuroendocrinol. 1998, 10:871-884.
53. Duffy J.F., Zeitzer J.M., Rimmer D.W., Klerman E.B., Dijk D.J., Czeisler C.A. Peak of circadian melatonin rhythm occurs later within the sleep of older subjects. Am. J. Physiol. Endocrinol. Metab. 2002, 282:E297-E303.
54. Dzirasa K., Ribeiro S., Costa R., Santos L.M., Lin S.C., Grosmark A., Sotnikova T.D., Gainetdinov R.R., Caron M.G., Nicolelis M.A. Dopaminergic control of sleep-wake states. J. Neurosci. 2006, 26:10577-10589.
55. Eisenberg D.P., Kohn P.D., Baller E.B., Bronstein J.A., Masdeu J.C., Berman K.F. Seasonal effects on human striatal presynaptic dopamine synthesis. J. Neurosci. 2010, 30:14691-14694.
56. Eisensehr I., Linke R., Noachtar S., Schwarz J., Gildehaus F.J., Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain 2000, 123(Pt 6):1155-1160.
57. Eisensehr I., Wetter T.C., Linke R., Noachtar S., von Lindeiner H., Gildehaus F.J., Trenkwalder C., Tatsch K. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001, 57:1307-1309.
58. Eisensehr I., Linke R., Tatsch K., Kharraz B., Gildehaus J.F., Wetter C.T., Trenkwalder C., Schwarz J., Noachtar S. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. Sleep 2003, 26:507-512.
59. Ejaz A.A., Sekhon I.S., Munjal S. Characteristic findings on 24-h ambulatory blood pressure monitoring in a series of patients with Parkinson's disease. Eur. J. Intern. Med. 2006, 17:417-420.
60. Ekbom K.A. Restless legs; a report of 70 new cases. Acta Med. Scand. Suppl. 1950, 246:64-68.
61. Fabbrini G., Barbanti P., Aurilia C., Vanacore N., Pauletti C., Meco G. Excessive daytime sleepiness in de novo and treated Parkinson's disease. Mov. Disord. 2002, 17:1026-1030.
62. Factor S.A., McAlarney T., Sanchez-Ramos J.R., Weiner W.J. Sleep disorders and sleep effect in Parkinson's disease. Mov. Disord. 1990, 5:280-285.
63. Fahn S., Libsch L.R., Cutler R.W. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J. Neurol. Sci. 1971, 14:427-455.
64. Fantini M.L., Gagnon J.F., Filipini D., Montplaisir J. The effects of pramipexole in REM sleep behavior disorder. Neurology 2003, 61:1418-1420.
65. Fantini M.L., Ferini-Strambi L., Montplaisir J. Idiopathic REM sleep behavior disorder: toward a better nosologic definition. Neurology 2005, 64:780-786.
66. Ferini-Strambi L., Franceschi M., Pinto P., Zucconi M., Smirne S. Respiration and heart rate variability during sleep in untreated Parkinson patients. Gerontology 1992, 38:92-98.
67. Ferini-Strambi L., Fantini M.L., Zucconi M., Castronovo V., Marelli S., Oldani A., Cappa S. REM sleep behaviour disorder. Neurol. Sci. 2005, 26(Suppl. 3):s186-s192.
68. Ferman T.J., Boeve B.F., Smith G.E., Silber M.H., Kokmen E., Petersen R.C., Ivnik R.J. REM sleep behavior disorder and dementia: cognitive differences when compared with AD. Neurology 1999, 52:951-957.
69. Fertl E., Auff E., Doppelbauer A., Waldhauser F. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. J. Neural. Transm. Park. Dis. Dement. Sect. 1993, 5:227-234.
70. Fox S.H., Brotchie J.M. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Prog. Brain Res. 2010, 184:133-157.
71. Fronczek R., Overeem S., Lee S.Y., Hegeman I.M., van Pelt J., van Duinen S.G., Lammers G.J., Swaab D.F. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007, 130:1577-1585.
72. Frucht S., Rogers J.D., Greene P.E., Gordon M.F., Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999, 52:1908-1910.
73. Fukutake T., Shinotoh H., Nishino H., Ichikawa Y., Goto J., Kanazawa I., Hattori T. Homozygous Machado-Joseph disease presenting as REM sleep behaviour disorder and prominent psychiatric symptoms. Eur. J. Neurol. 2002, 9:97-100.
74. Gagnon J.F., Bedard M.A., Fantini M.L., Petit D., Panisset M., Rompre S., Carrier J., Montplaisir J. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002, 59:585-589.
75. Gao X., Schwarzschild M.A., O'Reilly E.J., Wang H., Ascherio A. Restless legs syndrome and Parkinson's disease in men. Mov. Disord. 2010, 25:2654-2657.
76. Gao J., Huang X., Park Y., Hollenbeck A., Blair A., Schatzkin A., Chen H. Daytime napping, nighttime sleeping, and Parkinson disease. Am. J. Epidemiol. 2011, 173:1032-1038.
77. Garcia-Borreguero D., Larrosa O., Bravo M. Parkinson's disease and sleep. Sleep Med. Rev. 2003, 7:115-129.
78. Garcia-Borreguero D., Egatz R., Winkelmann J., Berger K. Epidemiology of restless legs syndrome: the current status. Sleep Med. Rev. 2006, 10:153-167.
79. Garfinkel D., Laudon M., Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs. Arch. Gerontol. Geriatr. 1997, 24:223-231.
80. Gjerstad M.D., Aarsland D., Larsen J.P. Development of daytime somnolence over time in Parkinson's disease. Neurology 2002, 58:1544-1546.
81. Godau J., Schweitzer K.J., Liepelt I., Gerloff C., Berg D. Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome. Mov. Disord. 2007, 22:187-192.
82. Golombek D.A., Rosenstein R.E. Physiology of circadian entrainment. Physiol. Rev. 2010, 90:1063-1102.
83. Gonzalez M.M., Aston-Jones G. Light deprivation damages monoamine neurons and produces a depressive behavioral phenotype in rats. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4898-4903.
84. Gravotta L., Gavrila A.M., Hood S., Amir S. Global depletion of dopamine using intracerebroventricular 6-hydroxydopamine injection disrupts normal circadian wheel-running patterns and PERIOD2 expression in the rat forebrain. J. Mol. Neurosci. 2011, 45:162-171.
85. Gruner J.A., Marcy V.R., Lin Y.G., Bozyczko-Coyne D., Marino M.J., Gasior M. The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents. Sleep 2009, 32:1425-1438.
86. Hampp G., Albrecht U. The circadian clock and mood-related behavior. Commun. Integr. Biol. 2008, 1:1-3.
87. Hampp G., Ripperger J.A., Houben T., Schmutz I., Blex C., Perreau-Lenz S., Brunk I., Spanagel R., Ahnert-Hilger G., Meijer J.H., Albrecht U. Regulation of monoamine oxidase A by circadian-clock components implies clock influence on mood. Curr. Biol. 2008, 18:678-683.
88. Happe S., Schrodl B., Faltl M., Muller C., Auff E., Zeitlhofer J. Sleep disorders and depression in patients with Parkinson's disease. Acta Neurol. Scand. 2001, 104:275-280.
89. Harper D.G., Volicer L., Stopa E.G., McKee A.C., Nitta M., Satlin A. Disturbance of endogenous circadian rhythm in aging and Alzheimer disease. Am. J. Geriatr. Psychiatry 2005, 13:359-368.
90. Harrell L.E., Balagura S. The effects of dark and light on the functional recovery following lateral hypothalamic lesions. Life Sci. 1974, 15:2079-2087.
91. Hartmann A., Veldhuis J.D., Deuschle M., Standhardt H., Heuser I. Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol. Aging 1997, 18:285-289.
92. Hirsh J., Riemensperger T., Coulom H., Iche M., Coupar J., Birman S. Roles of dopamine in circadian rhythmicity and extreme light sensitivity of circadian entrainment. Curr. Biol. 2010, 20:209-214.
93. Hjort N., Ostergaard K., Dupont E. Improvement of sleep quality in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. Mov. Disord. 2004, 19:196-199.
94. Hobson D.E., Lang A.E., Martin W.R., Razmy A., Rivest J., Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002, 287:455-463.
95. Hofman M.A. The human circadian clock and aging. Chronobiol. Int. 2000, 17:245-259.
96. Hogl B., Saletu M., Brandauer E., Glatzl S., Frauscher B., Seppi K., Ulmer H., Wenning G., Poewe W. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002, 25:905-909.
97. Hood S., Cassidy P., Cossette M.P., Weigl Y., Verwey M., Robinson B., Stewart J., Amir S. Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. J. Neurosci. 2010, 30:14046-14058.
98. Imbesi M., Yildiz S., Dirim Arslan A., Sharma R., Manev H., Uz T. Dopamine receptor-mediated regulation of neuronal "clock" gene expression. Neuroscience 2009, 158:537-544.
99. Iranzo A., Santamaria J., Rye D.B., Valldeoriola F., Marti M.J., Munoz E., Vilaseca I., Tolosa E. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 2005, 65:247-252.
100. Iranzo A., Santamaria J., Tolosa E. The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative diseases. Sleep Med. Rev. 2009, 13(6):385-401.
101. Isaac S.O., Berridge C.W. Wake-promoting actions of dopamine D1 and D2 receptor stimulation. J. Pharmacol. Exp. Ther. 2003, 307:386-394.
102. Ishida Y., Yokoyama C., Inatomi T., Yagita K., Dong X., Yan L., Yamaguchi S., Nagatsu I., Komori T., Kitahama K., Okamura H. Circadian rhythm of aromatic l-amino acid decarboxylase in the rat suprachiasmatic nucleus: gene expression and decarboxylating activity in clock oscillating cells. Genes Cells 2002, 7:447-459.
103. Jackson C.R., Chaurasia S.S., Hwang C.K., Iuvone P.M. Dopamine D(4) receptor activation controls circadian timing of the adenylyl cyclase 1/cyclic AMP signaling system in mouse retina. Eur. J. Neurosci. 2011, 34:57-64.
104. Jellinger K.A. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution-a pilot study. Acta Neuropathol. (Berl) 2003, 106:191-201.
105. Kafka M.S., Benedito M.A., Roth R.H., Steele L.K., Wolfe W.W., Catravas G.N. Circadian rhythms in catecholamine metabolites and cyclic nucleotide production. Chronobiol. Int. 1986, 3:101-115.
106. Kallio M., Haapaniemi T., Turkka J., Suominen K., Tolonen U., Sotaniemi K., Heikkila V.P., Myllyla V. Heart rate variability in patients with untreated Parkinson's disease. Eur. J. Neurol. 2000, 7:667-672.
107. Karlsen K.H., Larsen J.P., Tandberg E., Maeland J.G. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1999, 66:431-435.
108. Kaynak D., Kiziltan G., Kaynak H., Benbir G., Uysal O. Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment. Eur. J. Neurol. 2005, 12:199-207.
109. Khaldy H., Leon J., Escames G., Bikjdaouene L., Garcia J.J., Acuna-Castroviejo D. Circadian rhythms of dopamine and dihydroxyphenyl acetic acid in the mouse striatum: effects of pinealectomy and of melatonin treatment. Neuroendocrinology 2002, 75:201-208.
110. Kimura K., Tachibana N., Kohyama J., Otsuka Y., Fukazawa S., Waki R. A discrete pontine ischemic lesion could cause REM sleep behavior disorder. Neurology 2000, 55:894-895.
111. King S.A. Pain in depression and Parkinson's disease. Am. J. Psychiatry 1993, 150:353-354.
112. Korner Y., Meindorfner C., Moller J.C., Stiasny-Kolster K., Haja D., Cassel W., Oertel W.H., Kruger H.P. Predictors of sudden onset of sleep in Parkinson's disease. Mov. Disord. 2004, 19:1298-1305.
113. Krishnan P.R., Bhatia M., Behari M. Restless legs syndrome in Parkinson's disease: a case-controlled study. Mov. Disord. 2003, 18:181-185.
114. Kudo T., Loh D.H., Truong D., Wu Y., Colwell C.S. Circadian dysfunction in a mouse model of Parkinson's disease. Exp. Neurol. 2011, 232:66-75.
115. Kumar S., Bhatia M., Behari M. Sleep disorders in Parkinson's disease. Mov. Disord. 2002, 17:775-781.
116. Kunz D., Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov. Disord. 1999, 14:507-511.
117. Laloux C., Derambure P., Houdayer E., Jacquesson J.M., Bordet R., Destee A., Monaca C. Effect of dopaminergic substances on sleep/wakefulness in saline- and MPTP-treated mice. J. Sleep Res. 2008, 17:101-110.
118. Lees A.J., Blackburn N.A., Campbell V.L. The nighttime problems of Parkinson's disease. Clin. Neuropharmacol. 1988, 11:512-519.
119. Lima M.M., Andersen M.L., Reksidler A.B., Vital M.A., Tufik S. The role of the substantia nigra pars compacta in regulating sleep patterns in rats. PLoS One 2007, 2:e513.
120. Lugaresi E., Coccagna G., Gambi D., Berti Ceroni G., Poppi M. Symonds' nocturnal myoclonus. Electroencephalogr. Clin. Neurophysiol. 1967, 23:289.
121. MacFarlane J.G., Cleghorn J.M., Brown G.M., Streiner D.L. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biol. Psychiatry 1991, 30:371-376.
122. Mahowald M.W., Schenck C.H. REM Sleep Parasomnias, Principles and Practice of Sleep Medicine 2005, 897-916. Elsevier Sounders, Philadelphia.
123. Manni R., Terzaghi M., Sartori I., Mancini F., Pacchetti C. Dopamine agonists and sleepiness in PD: review of the literature and personal findings. Sleep Med. 2004, 5:189-193.
124. Maria B., Sophia S., Michalis M., Charalampos L., Andreas P., John M.E., Nikolaos S.M. Sleep breathing disorders in patients with idiopathic Parkinson's disease. Respir. Med. 2003, 97:1151-1157.
125. Marinus J., Visser M., van Hilten J.J., Lammers G.J., Stiggelbout A.M. Assessment of sleep and sleepiness in Parkinson disease. Sleep 2003, 26:1049-1054.
126. Matzuk M.M., Saper C.B. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease. Ann. Neurol. 1985, 18:552-555.
127. McClung C.A. Circadian rhythms, the mesolimbic dopaminergic circuit, and drug addiction. ScientificWorldJournal 2007, 7:194-202.
128. McClung C.A., Sidiropoulou K., Vitaterna M., Takahashi J.S., White F.J., Cooper D.C., Nestler E.J. Regulation of dopaminergic transmission and cocaine reward by the Clock gene. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9377-9381.
129. Mehta S.H., Morgan J.C., Sethi K.D. Sleep disorders associated with Parkinson's disease: role of dopamine, epidemiology, and clinical scales of assessment. CNS Spectr. 2008, 13:6-11.
130. Mendoza J., Clesse D., Pevet P., Challet E. Food-reward signalling in the suprachiasmatic clock. J. Neurochem. 2010, 112:1489-1499.
131. Mihci E., Kardelen F., Dora B., Balkan S. Orthostatic heart rate variability analysis in idiopathic Parkinson's disease. Acta Neurol. Scand. 2006, 113:288-293.
132. Monaca C., Laloux C., Jacquesson J.M., Gele P., Marechal X., Bordet R., Destee A., Derambure P. Vigilance states in a parkinsonian model, the MPTP mouse. Eur. J. Neurosci. 2004, 20:2474-2478.
133. Montastruc J.L., Brefel-Courbon C., Senard J.M., Bagheri H., Ferreira J., Rascol O., Lapeyre-Mestre M. Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin. Neuropharmacol. 2001, 24:181-183.
134. Monti J.M., Jantos H. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking. Prog. Brain Res. 2008, 172:625-646.
135. Monti J.M., Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med. Rev. 2007, 11:113-133.
136. Monti J.M., Hawkins M., Jantos H., D'Angelo L., Fernandez M. Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat. Psychopharmacology (Berl) 1988, 95:395-400.
137. Murillo-Rodriguez E., Arias-Carrion O., Sanguino-Rodriguez K., Gonzalez-Arias M., Haro R. Mechanisms of sleep-wake cycle modulation. CNS Neurol. Disord. Drug Targets 2009, 8:245-253.
138. Nomura T., Inoue Y., Miyake M., Yasui K., Nakashima K. Prevalence and clinical characteristics of restless legs syndrome in Japanese patients with Parkinson's disease. Mov. Disord. 2006, 21:380-384.
139. Norlinah M.I., Afidah K.N., Noradina A.T., Shamsul A.S., Hamidon B.B., Sahathevan R., Raymond A.A. Sleep disturbances in Malaysian patients with Parkinson's disease using polysomnography and PDSS. Parkinsonism Relat. Disord. 2009, 15:670-674.
140. Nutt J.G., Woodward W.R., Carter J.H., Trotman T.L. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J. Neurol. Neurosurg. Psychiatry 1989, 52:481-487.
141. Ohayon M.M., Caulet M., Priest R.G. Violent behavior during sleep. J. Clin. Psychiatry 1997, 58:369-376. (quiz 377).
142. Olson E.J., Boeve B.F., Silber M.H. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000, 123(Pt 2):331-339.
143. Ondo W.G., Dat Vuong K., Khan H., Atassi F., Kwak C., Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001, 57:1392-1396.
144. Ondo W.G., Vuong K.D., Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch. Neurol. 2002, 59:421-424.
145. Ondo W.G., Fayle R., Atassi F., Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J. Neurol. Neurosurg. Psychiatry 2005, 76:1636-1639.
146. Ozekmekci S., Apaydin H., Kilic E. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder. Clin. Neurol. Neurosurg. 2005, 107:306-309.
147. Pacchetti C., Manni R., Zangaglia R., Mancini F., Marchioni E., Tassorelli C., Terzaghi M., Ossola M., Martignoni E., Moglia A., Nappi G. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov. Disord. 2005, 20:1439-1448.
148. Pahwa R., Busenbark K., Huber S.J., Michalek D., Hubble J.P., Koller W.C. Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease. Neurology 1993, 43:677-681.
149. Pastor P., Tolosa E. Cabergoline in the treatment of Parkinson's disease. Neurologia 2003, 18:202-209.
150. Pathak A., Senard J.M. Blood pressure disorders during Parkinson's disease: epidemiology, pathophysiology and management. Expert. Rev. Neurother. 2006, 6:1173-1180.
151. Paus S., Brecht H.M., Koster J., Seeger G., Klockgether T., Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov. Disord. 2003, 18:659-667.
152. Paus S., Schmitz-Hubsch T., Wullner U., Vogel A., Klockgether T., Abele M. Bright light therapy in Parkinson's disease: a pilot study. Mov. Disord. 2007, 22:1495-1498.
153. Piccini P., Del Dotto P., Pardini C., D'Antonio P., Rossi G., Bonuccelli U. Diurnal worsening in Parkinson patients treated with levodopa. Riv. Neurol. 1991, 61:219-224.
154. Pierangeli G., Provini F., Maltoni P., Barletta G., Contin M., Lugaresi E., Montagna P., Cortelli P. Nocturnal body core temperature falls in Parkinson's disease but not in multiple-system atrophy. Mov. Disord. 2001, 16:226-232.
155. Placidi F., Izzi F., Romigi A., Stanzione P., Marciani M.G., Brusa L., Sperli F., Galati S., Pasqualetti P., Pierantozzi M. Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study. J. Neurol. 2008, 255:1032-1037.
156. Plaschke M., Trenkwalder P., Dahlheim H., Lechner C., Trenkwalder C. Twenty-four-hour blood pressure profile and blood pressure responses to head-up tilt tests in Parkinson's disease and multiple system atrophy. J. Hypertens. 1998, 16:1433-1441.
157. Plazzi G., Corsini R., Provini F., Pierangeli G., Martinelli P., Montagna P., Lugaresi E., Cortelli P. REM sleep behavior disorders in multiple system atrophy. Neurology 1997, 48:1094-1097.
158. Poewe W., Hogl B. Akathisia, restless legs and periodic limb movements in sleep in Parkinson's disease. Neurology 2004, 63:S12-S16.
159. Porter B., Macfarlane R., Walker R. The frequency and nature of sleep disorders in a community-based population of patients with Parkinson's disease. Eur. J. Neurol. 2008, 15:50-54.
160. Postuma R.B., Gagnon J.F., Vendette M., Charland K., Montplaisir J. REM sleep behaviour disorder in Parkinson's disease is associated with specific motor features. J. Neurol. Neurosurg. Psychiatry 2008, 79:1117-1121.
161. Postuma R.B., Gagnon J.F., Vendette M., Fantini M.L., Massicotte-Marquez J., Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009, 72:1296-1300.
162. PSG Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000, 284:1931-1938.
163. Pungor K., Papp M., Kekesi K., Juhasz G. A novel effect of MPTP: the selective suppression of paradoxical sleep in cats. Brain Res. 1990, 525:310-314.
164. Pursiainen V., Haapaniemi T.H., Korpelainen J.T., Huikuri H.V., Sotaniemi K.A., Myllyla V.V. Circadian heart rate variability in Parkinson's disease. J. Neurol. 2002, 249:1535-1540.
165. Qu W.M., Huang Z.L., Xu X.H., Matsumoto N., Urade Y. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J. Neurosci. 2008, 28:8462-8469.
166. Qu W.M., Xu X.H., Yan M.M., Wang Y.Q., Urade Y., Huang Z.L. Essential role of dopamine D2 receptor in the maintenance of wakefulness, but not in homeostatic regulation of sleep, in mice. J. Neurosci. 2010, 30:4382-4389.
167. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 2000, 342:1484-1491.
168. Reinberg A., Ashkenazi I. Internal desynchronization of circadian rhythms and tolerance to shift work. Chronobiol. Int. 2008, 25:625-643.
169. Reinberg A., Proux S., Bartal J.P., Levi F., Bicakova-Rocher A. Circadian rhythms in competitive sabre fencers: internal desynchronization and performance. Chronobiol. Int. 1985, 2:195-201.
170. Ringman J.M., Simmons J.H. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 2000, 55:870-871.
171. Roth T., Rye D.B., Borchert L.D., Bartlett C., Bliwise D.L., Cantor C., Gorell J.M., Hubble J.P., Musch B., Olanow C.W., Pollak C., Stern M.B., Watts R.L. Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med. 2003, 4:275-280.
172. Roybal K., Theobold D., Graham A., DiNieri J.A., Russo S.J., Krishnan V., Chakravarty S., Peevey J., Oehrlein N., Birnbaum S., Vitaterna M.H., Orsulak P., Takahashi J.S., Nestler E.J., Carlezon W.A., McClung C.A. Mania-like behavior induced by disruption of CLOCK. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:6406-6411.
173. Ruan G.X., Allen G.C., Yamazaki S., McMahon D.G. An autonomous circadian clock in the inner mouse retina regulated by dopamine and GABA. PLoS Biol. 2008, 6:e249.
174. Ruottinen H.M., Partinen M., Hublin C., Bergman J., Haaparanta M., Solin O., Rinne J.O. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000, 54:502-504.
175. Rye D.B. Parkinson's disease and RLS: the dopaminergic bridge. Sleep Med. 2004, 5:317-328.
176. Rye D.B. The two faces of Eve: dopamine's modulation of wakefulness and sleep. Neurology 2004, 63:S2-S7.
177. Rye D. Seeing beyond one's nose: sleep disruption and excessive sleepiness accompany motor disability in the MPTP treated primate. Exp. Neurol. 2010, 222:179-180.
178. Rye D.B., Bliwise D.L., Dihenia B., Gurecki P. FAST TRACK: daytime sleepiness in Parkinson's disease. J. Sleep Res. 2000, 9:63-69.
179. Sakamoto K., Liu C., Kasamatsu M., Pozdeyev N.V., Iuvone P.M., Tosini G. Dopamine regulates melanopsin mRNA expression in intrinsically photosensitive retinal ganglion cells. Eur. J. Neurosci. 2005, 22:3129-3136.
180. Scaglione C., Vignatelli L., Plazzi G., Marchese R., Negrotti A., Rizzo G., Lopane G., Bassein L., Maestri M., Bernardini S., Martinelli P., Abbruzzese G., Calzetti S., Bonuccelli U., Provini F., Coccagna G. REM sleep behaviour disorder in Parkinson's disease: a questionnaire-based study. Neurol. Sci. 2005, 25:316-321.
181. Schafer H., Pauleit D., Sudhop T., Gouni-Berthold I., Ewig S., Berthold H.K. Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. Chest 2002, 122:829-839.
182. Schenck C.H., Mahowald M.W. Motor dyscontrol in narcolepsy: rapid-eye-movement (REM) sleep without atonia and REM sleep behavior disorder. Ann. Neurol. 1992, 32:3-10.
183. Schenck C.H., Mahowald M.W. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16years after its formal identification in SLEEP. Sleep 2002, 25:120-138.
184. Schenck C.H., Mahowald M.W. Rapid eye movement sleep parasomnias. Neurol. Clin. 2005, 23:1107-1126.
185. Schenck C.H., Bundlie S.R., Ettinger M.G., Mahowald M.W. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 1986, 9:293-308.
186. Schenck C.H., Bundlie S.R., Mahowald M.W. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996, 46:388-393.
187. Schenck C.H., Mahowald M.W., Anderson M.L., Silber M.H., Boeve B.F., Parisi J.E. Lewy body variant of Alzheimer's disease (AD) identified by postmortem ubiquitin staining in a previously reported case of AD associated with REM sleep behavior disorder. Biol. Psychiatry 1997, 42:527-528.
188. Schmidauer C., Sojer M., Seppi K., Stockner H., Hogl B., Biedermann B., Brandauer E., Peralta C.M., Wenning G.K., Poewe W. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann. Neurol. 2005, 58:630-634.
189. Senard J.M., Chamontin B., Rascol A., Montastruc J.L. Ambulatory blood pressure in patients with Parkinson's disease without and with orthostatic hypotension. Clin. Auton. Res. 1992, 2:99-104.
190. Shang Y., Haynes P., Pirez N., Harrington K.I., Guo F., Pollack J., Hong P., Griffith L.C., Rosbash M. Imaging analysis of clock neurons reveals light buffers the wake-promoting effect of dopamine. Nat. Neurosci. 2011, 14:889-895.
191. Shirani A., St Louis E.K. Illuminating rationale and uses for light therapy. J. Clin. Sleep Med. 2009, 5:155-163.
192. Shulman L.M., Taback R.L., Bean J., Weiner W.J. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov. Disord. 2001, 16:507-510.
193. Silva E.J., Wang W., Ronda J.M., Wyatt J.K., Duffy J.F. Circadian and wake-dependent influences on subjective sleepiness, cognitive throughput, and reaction time performance in older and young adults. Sleep 2010, 33:481-490.
194. Sixel-Doring F., Trautmann E., Mollenhauer B., Trenkwalder C. Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology 2011, 77:1048-1054.
195. Sleipness E.P., Sorg B.A., Jansen H.T. Contribution of the suprachiasmatic nucleus to day:night variation in cocaine-seeking behavior. Physiol. Behav. 2007, 91:523-530.
196. Sleipness E.P., Sorg B.A., Jansen H.T. Diurnal differences in dopamine transporter and tyrosine hydroxylase levels in rat brain: dependence on the suprachiasmatic nucleus. Brain Res. 2007, 1129:34-42.
197. Stevens S., Cormella C.L., Stepanski E.J. Daytime sleepiness and alertness in patients with Parkinson disease. Sleep 2004, 27:967-972.
198. Strieder D.J., Baker W.G., Baringer J.R., Kazemi H. Chronic hypoventilation of central origin. A case with encephalitis lethargica and Parkinson's syndrome. Am. Rev. Respir. Dis. 1967, 96:501-507.
199. Struck L.K., Rodnitzky R.L., Dobson J.K. Circadian fluctuations of contrast sensitivity in Parkinson's disease. Neurology 1990, 40:467-470.
200. Suzuki K., Miyamoto T., Miyamoto M., Kaji Y., Takekawa H., Hirata K. Circadian variation of core body temperature in Parkinson disease patients with depression: a potential biological marker for depression in Parkinson disease. Neuropsychobiology 2007, 56:172-179.
201. Syed B.H., Rye D.B., Singh G. REM sleep behavior disorder and SCA-3 (Machado-Joseph disease). Neurology 2003, 60:148.
202. Tachibana N., Kimura K., Kitajima K., Shinde A., Kimura J., Shibasaki H. REM sleep motor dysfunction in multiple system atrophy: with special emphasis on sleep talk as its early clinical manifestation. J. Neurol. Neurosurg. Psychiatry 1997, 63:678-681.
203. Tan E.K., Lum S.Y., Wong M.C. Restless legs syndrome in Parkinson's disease. J. Neurol. Sci. 2002, 196:33-36.
204. Tandberg E., Larsen J.P., Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov. Disord. 1998, 13:895-899.
205. Thannickal T.C., Lai Y.Y., Siegel J.M. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007, 130:1586-1595.
206. Touitou Y., Haus E. Alterations with aging of the endocrine and neuroendocrine circadian system in humans. Chronobiol. Int. 2000, 17:369-390.
207. Trenkwalder C., Kohnen R., Hogl B., Metta V., Sixel-Doring F., Frauscher B., Hulsmann J., Martinez-Martin P., Chaudhuri K.R. Parkinson's disease sleep scale-validation of the revised version PDSS-2. Mov. Disord. 2011, 26:644-652.
208. Trotti L.M., Bliwise D.L. No increased risk of obstructive sleep apnea in Parkinson's disease. Mov. Disord. 2010, 25:2246-2249.
209. Turek F.W., Penev P., Zhang Y., van Reeth O., Zee P. Effects of age on the circadian system. Neurosci. Biobehav. Rev. 1995, 19:53-58.
210. Turjanski N., Lees A.J., Brooks D.J. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999, 52:932-937.
211. Turner W.A., Critchley M. Respiratory disorders in epidemic encephalitis. Brain 1925, 48:72-104.
212. van Coevorden A., Mockel J., Laurent E., Kerkhofs M., L'Hermite-Baleriaux M., Decoster C., Neve P., Van Cauter E. Neuroendocrine rhythms and sleep in aging men. Am. J. Physiol. 1991, 260:E651-E661.
213. van den Heuvel C.J., Lushington K. Chronobiology and insomnia: pathophysiology and treatment of circadian rhythm sleep disorders. Expert. Rev. Neurother. 2002, 2:249-260.
214. Van den Kerchove M., Jacquy J., Gonce M., De Deyn P.P. Sustained-release levodopa in parkinsonian patients with nocturnal disabilities. Acta Neurol. Belg. 1993, 93:32-39.
215. van Hilten J.J., Middelkoop H.A., Kerkhof G.A., Roos R.A. A new approach in the assessment of motor activity in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1991, 54:976-979.
216. van Hilten J.J., Hoogland G., van der Velde E.A., Middelkoop H.A., Kerkhof G.A., Roos R.A. Diurnal effects of motor activity and fatigue in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1993, 56:874-877.
217. van Hilten J.J., Kabel J.F., Middelkoop H.A., Kramer C.G., Kerkhof G.A., Roos R.A. Assessment of response fluctuations in Parkinson's disease by ambulatory wrist activity monitoring. Acta Neurol. Scand. 1993, 87:171-177.
218. van Hilten J.J., Weggeman M., van der Velde E.A., Kerkhof G.A., van Dijk J.G., Roos R.A. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J. Neural. Transm. Park. Dis. Dement. Sect. 1993, 5:235-244.
219. van Hilten B., Hoff J.I., Middelkoop H.A., van der Velde E.A., Kerkhof G.A., Wauquier A., Kamphuisen H.A., Roos R.A. Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring. Arch. Neurol. 1994, 51:922-928.
220. van Vliet S.A., Vanwersch R.A., Jongsma M.J., van der Gugten J., Olivier B., Philippens I.H. Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects. Behav. Pharmacol. 2006, 17:453-462.
221. Verbaan D., van Rooden S.M., Visser M., Marinus J., van Hilten J.J. Nighttime sleep problems and daytime sleepiness in Parkinson's disease. Mov. Disord. 2008, 23:35-41.
222. Verhave P.S., Jongsma M.J., Van den Berg R.M., Vis J.C., Vanwersch R.A., Smit A.B., Van Someren E.J., Philippens I.H. REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease. Sleep 2011, 34:1119-1125.
223. Viswanathan N., Weaver D.R., Reppert S.M., Davis F.C. Entrainment of the fetal hamster circadian pacemaker by prenatal injections of the dopamine agonist SKF 38393. J. Neurosci. 1994, 14:5393-5398.
224. Viyoch J., Matsunaga N., Yoshida M., To H., Higuchi S., Ohdo S. Effect of haloperidol on mPer1 gene expression in mouse suprachiasmatic nuclei. J. Biol. Chem. 2005, 280:6309-6315.
225. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., Telang F., Wang G.J., Jayne M., Hooker J.M., Wong C., Hubbard B., Carter P., Warner D., King P., Shea C., Xu Y., Muench L., Apelskog-Torres K. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009, 301:1148-1154.
226. Walters A.S., Hening W., Rubinstein M., Chokroverty S. A clinical and polysomnographic comparison of neuroleptic-induced akathisia and the idiopathic restless legs syndrome. Sleep 1991, 14:339-345.
227. Waterhouse J. Circadian rhythms and cognition. Prog. Brain Res. 2010, 185:131-153.
228. Weaver D.R., Rivkees S.A., Reppert S.M. D1-dopamine receptors activate c-fos expression in the fetal suprachiasmatic nuclei. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:9201-9204.
229. Webb I.C., Baltazar R.M., Lehman M.N., Coolen L.M. Bidirectional interactions between the circadian and reward systems: is restricted food access a unique zeitgeber?. Eur. J. Neurosci. 2009, 30:1739-1748.
230. Weber M., Lauterburg T., Tobler I., Burgunder J.M. Circadian patterns of neurotransmitter related gene expression in motor regions of the rat brain. Neurosci. Lett. 2004, 358:17-20.
231. Wetter T.C., Collado-Seidel V., Pollmacher T., Yassouridis A., Trenkwalder C. Sleep and periodic leg movement patterns in drug-free patients with Parkinson's disease and multiple system atrophy. Sleep 2000, 23:361-367.
232. Wetter T.C., Brunner H., Collado-Seidel V., Trenkwalder C., Winkelmann J. Sleep and periodic limb movements in corticobasal degeneration. Sleep Med. 2002, 3:33-36.
233. Whitehead D.L., Davies A.D., Playfer J.R., Turnbull C.J. Circadian rest-activity rhythm is altered in Parkinson's disease patients with hallucinations. Mov. Disord. 2008, 23:1137-1145.
234. Willis G.L., Turner E.J. Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study. Chronobiol. Int. 2007, 24:521-537.
235. Wirz-Justice A., Da Prada M., Reme C. Circadian rhythm in rat retinal dopamine. Neurosci. Lett. 1984, 45:21-25.
236. Wisor J.P., Nishino S., Sora I., Uhl G.H., Mignot E., Edgar D.M. Dopaminergic role in stimulant-induced wakefulness. J. Neurosci. 2001, 21:1787-1794.
237. Witkovsky P. Dopamine and retinal function. Doc. Ophthalmol. 2004, 108:17-40.
238. Wulff K., Gatti S., Wettstein J.G., Foster R.G. Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. Nat. Rev. Neurosci. 2010, 11:589-599.
239. Young A., Home M., Churchward T., Freezer N., Holmes P., Ho M. Comparison of sleep disturbance in mild versus severe Parkinson's disease. Sleep 2002, 25:573-577.
240. Zambelis T., Paparrigopoulos T., Soldatos C.R. REM sleep behaviour disorder associated with a neurinoma of the left pontocerebellar angle. J. Neurol. Neurosurg. Psychiatry 2002, 72:821-822.
241. Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell. Mol. Neurobiol. 2001, 21:605-616.